Mechanisms of Receptor Tyrosine-Protein Kinase ErbB-3 (ERBB3) Action in Human Neoplasia

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2019 Jul 29

PMID 31351986

Citations 29

Authors

Laurel E Black

Jody F Longo

Steven L Carroll

Affiliations

Soon will be listed here.

Abstract

It is well established that the epidermal growth factor (EGF) receptor, receptor tyrosine-protein kinase erbB-2 (ERBB2)/human EGF receptor 2 (HER2), and, to a lesser extent, ERBB4/HER4, promote the pathogenesis of many types of human cancers. In contrast, the role that ERBB3/HER3, the fourth member of the ERBB family of receptor tyrosine kinases, plays in these diseases is poorly understood and, until recently, underappreciated. In large part, this was because early structural and functional studies suggested that ERBB3 had little, if any, intrinsic tyrosine kinase activity and, thus, was unlikely to be an important therapeutic target. Since then, however, numerous publications have demonstrated an important role for ERBB3 in carcinogenesis, metastasis, and acquired drug resistance. Furthermore, somatic ERBB3 mutations are frequently encountered in many types of human cancers. Dysregulation of ERBB3 trafficking as well as cooperation with other receptor tyrosine kinases further enhance ERBB3's role in tumorigenesis and drug resistance. As a result of these advances in our understanding of the structure and biochemistry of ERBB3, and a growing focus on the development of precision and combinatorial therapeutic regimens, ERBB3 is increasingly considered to be an important therapeutic target in human cancers. In this review, we discuss the unique structural and functional features of ERBB3 and how this information is being used to develop effective new therapeutic agents that target ERBB3 in human cancers.

Citing Articles

Emerging importance of HER3 in tumorigenesis and cancer therapy.

Garrett J, Tendler S, Feroz W, Kilroy M, Yu H Nat Rev Clin Oncol. 2025; .

PMID: 40087402 DOI: 10.1038/s41571-025-01008-y.

Multiple ligands simultaneous molecular docking and dynamics approach to study the synergetic inhibitory of curcumin analogs on ErbB4 tyrosine phosphorylation.

Aman L, Ischak N, Tuloli T, Arfan A, Asnawi A Res Pharm Sci. 2025; 19(6):754-765.

PMID: 39911900 PMC: 11792710. DOI: 10.4103/RPS.RPS_191_23.

Advances on the therapeutic potential of cell receptor activation in glioblastoma.

Contreras-Chavez G, Zapi-Colin L, Contreras I, Estrada J Mol Biol Rep. 2025; 52(1):207.

PMID: 39907852 DOI: 10.1007/s11033-025-10312-w.

Oxidative State in Cutaneous Melanoma Progression: A Question of Balance.

Benedusi M, Lee H, Lim Y, Valacchi G Antioxidants (Basel). 2024; 13(9).

PMID: 39334716 PMC: 11428248. DOI: 10.3390/antiox13091058.

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy.

Kumar R, Goel H, Solanki R, Rawat L, Tabasum S, Tanwar P Med Drug Discov. 2024; 23.

PMID: 39281823 PMC: 11393807. DOI: 10.1016/j.medidd.2024.100195.

References

Telesco S, Shih A, Liu Y, Radhakrishnan R . Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation. Cancer Res J. 2014; 4(4):1-35. PMC: 4208668. View

Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R . Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995; 378(6555):390-4. DOI: 10.1038/378390a0. View

Hynes N, MacDonald G . ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21(2):177-84. DOI: 10.1016/j.ceb.2008.12.010. View

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

Ni C, Murphy M, Golde T, Carpenter G . gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001; 294(5549):2179-81. DOI: 10.1126/science.1065412. View

Plowman G, Culouscou J, Whitney G, Green J, Carlton G, Foy L . Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A. 1993; 90(5):1746-50. PMC: 45956. DOI: 10.1073/pnas.90.5.1746. View

Nielsen T, Sorensen S, Dagnaes-Hansen F, Kjems J, Sorensen B . Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo. Br J Cancer. 2013; 108(11):2291-8. PMC: 3681029. DOI: 10.1038/bjc.2013.247. View

Jura N, Endres N, Engel K, Deindl S, Das R, Lamers M . Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell. 2009; 137(7):1293-307. PMC: 2814540. DOI: 10.1016/j.cell.2009.04.025. View

Schulze W, Deng L, Mann M . Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol. 2006; 1:2005.0008. PMC: 1681463. DOI: 10.1038/msb4100012. View

10.

Vecchi M, Carpenter G . Constitutive proteolysis of the ErbB-4 receptor tyrosine kinase by a unique, sequential mechanism. J Cell Biol. 1997; 139(4):995-1003. PMC: 2139967. DOI: 10.1083/jcb.139.4.995. View

11.

Wu Y, Zhang Y, Wang M, Li Q, Qu Z, Shi V . Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther. 2013; 12(4):427-37. DOI: 10.1158/1535-7163.MCT-12-0838. View

12.

Capone E, Lamolinara A, DAgostino D, Rossi C, De Laurenzi V, Iezzi M . EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. J Control Release. 2018; 277:48-56. DOI: 10.1016/j.jconrel.2018.03.016. View

13.

Scheeff E, Eswaran J, Bunkoczi G, Knapp S, Manning G . Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure. 2009; 17(1):128-38. PMC: 2639636. DOI: 10.1016/j.str.2008.10.018. View

14.

Lemmon M . Ligand-induced ErbB receptor dimerization. Exp Cell Res. 2008; 315(4):638-48. PMC: 2667204. DOI: 10.1016/j.yexcr.2008.10.024. View

15.

Naresh A, Thor A, Edgerton S, Torkko K, Kumar R, Jones F . The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 2008; 68(15):6387-95. PMC: 2538429. DOI: 10.1158/0008-5472.CAN-08-0538. View

16.

El Maassarani M, Barbarin A, Fromont G, Kaissi O, Lebbe M, Vannier B . Integrated and Functional Genomics Analysis Validates the Relevance of the Nuclear Variant ErbB380kDa in Prostate Cancer Progression. PLoS One. 2016; 11(5):e0155950. PMC: 4871423. DOI: 10.1371/journal.pone.0155950. View

17.

Adilakshmi T, Ness-Myers J, Madrid-Aliste C, Fiser A, Tapinos N . A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination. J Neurosci. 2011; 31(13):5106-19. PMC: 3086203. DOI: 10.1523/JNEUROSCI.5635-10.2011. View

18.

Andrique L, Fauvin D, El Maassarani M, Colasson H, Vannier B, Seite P . ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF. Cell Signal. 2012; 24(5):1074-85. DOI: 10.1016/j.cellsig.2012.01.002. View

19.

Wieduwilt M, Moasser M . The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008; 65(10):1566-84. PMC: 3060045. DOI: 10.1007/s00018-008-7440-8. View

20.

Brewer M, Choi S, Alvarado D, Moravcevic K, Pozzi A, Lemmon M . The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell. 2009; 34(6):641-51. PMC: 2719887. DOI: 10.1016/j.molcel.2009.04.034. View